ResearcherUniversity of MiamiActive in the last 2 years
Caitlin A. Hester
Matched on ORCID iD 0000-0002-3302-0839; OpenAlex author ID A5043889649. Sources: OpenAlex.
Their work
- Papers
- 13 (first author 1, last author 3)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 49
2020: 1 paper · 2021: 1 paper · 2022: 2 papers · 2023: 2 papers · 2024: 2 papers · 2025: 3 papers · 2026: 2 papers
Papers 13
- Factors Driving Attrition from Neoadjuvant Therapy to Pancreatectomy in Localized Pancreatic Cancer. Last author DOI 10.1245/s10434-025-18664-0↗
- ASO Visual Abstract: Factors Driving Attrition from Neoadjuvant Therapy to Pancreatectomy in Localized Pancreatic Cancer. Last author DOI 10.1245/s10434-025-18846-w↗
- Intersection of Black race and carbohydrate antigen 19-9 nonproduction underpins worse pathologic response to neoadjuvant therapy in pancreatic cancer. Last author DOI 10.1002/cncr.70130↗
- SMAD4 Alterations are a Predictive Biomarker to Guide First-line Chemotherapy Selection for the Neoadjuvant Treatment of Localized Pancreatic Cancer : A Multic… Co-author DOI 10.1097/sla.0000000000006966↗
- Neighborhood Disadvantage is Associated with Worse Pathologic Response in Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-17024-2↗
- Lymph node metrics following neoadjuvant therapy to refine patient selection for adjuvant chemotherapy in resected pancreatic cancer: A multi-institutional ana… Co-author DOI 10.1002/jso.27798↗
- Improving patient stratification and selection for curative-intent treatment in localized pancreatic cancer. Co-author DOI 10.21037/hbsn-23-668↗
- ASO Author Reflections: Racial Disparities in Chemoresponsivity in Localized Pancreatic Cancer: Nature or Nurture? Co-author DOI 10.1245/s10434-022-12843-z↗
- Hospital Designations and Their Impact on Guideline-Concordant Care and Survival in Pancreatic Cancer. Do They Matter? Co-author DOI 10.1245/s10434-023-13308-7↗
- A patient-centered, multidisciplinary approach to treating borderline resectable pancreatic adenocarcinoma. Co-author DOI 10.21037/cco-22-86↗
- Radiographic and Serologic Response to First-Line Chemotherapy in Unresected Localized Pancreatic Cancer. Co-author DOI 10.6004/jnccn.2022.7018↗
- Thumbprinting Locally Advanced Pancreatic Cancer: Have We Developed the Optimal Staging System? Co-author DOI 10.1245/s10434-021-10181-0↗
- Clinicopathologic Features and Outcomes of Early-Onset Pancreatic Adenocarcinoma in the United States. First author DOI 10.1245/s10434-019-08096-y↗
Closest collaborators
The 25 strongest of 49 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Nipun B. Merchant · 8 shared papers, 2023–2026 · strength 1.87
- Paper Factors Driving Attrition from Neoadjuvant Therapy to Pancreatectomy in Localized Pancreatic Cancer. DOI 10.1245/s10434-025-18664-0↗
- Paper ASO Visual Abstract: Factors Driving Attrition from Neoadjuvant Therapy to Pancreatectomy in Localized Pancreatic Cance… DOI 10.1245/s10434-025-18846-w↗
- Paper ASO Author Reflections: Racial Disparities in Chemoresponsivity in Localized Pancreatic Cancer: Nature or Nurture? DOI 10.1245/s10434-022-12843-z↗
- Mary P Martos · 6 shared papers, 2024–2026 · strength 1.42
- Paper Factors Driving Attrition from Neoadjuvant Therapy to Pancreatectomy in Localized Pancreatic Cancer. DOI 10.1245/s10434-025-18664-0↗
- Paper ASO Visual Abstract: Factors Driving Attrition from Neoadjuvant Therapy to Pancreatectomy in Localized Pancreatic Cance… DOI 10.1245/s10434-025-18846-w↗
- Paper Neighborhood Disadvantage is Associated with Worse Pathologic Response in Pancreatic Cancer. DOI 10.1245/s10434-025-17024-2↗
- Erin M. Dickey · 6 shared papers, 2024–2026 · strength 1.35
- Paper Factors Driving Attrition from Neoadjuvant Therapy to Pancreatectomy in Localized Pancreatic Cancer. DOI 10.1245/s10434-025-18664-0↗
- Paper ASO Visual Abstract: Factors Driving Attrition from Neoadjuvant Therapy to Pancreatectomy in Localized Pancreatic Cance… DOI 10.1245/s10434-025-18846-w↗
- Paper Improving patient stratification and selection for curative-intent treatment in localized pancreatic cancer. DOI 10.21037/hbsn-23-668↗
- Jashodeep Datta · 5 shared papers, 2023–2026 · strength 1.27
- Paper Factors Driving Attrition from Neoadjuvant Therapy to Pancreatectomy in Localized Pancreatic Cancer. DOI 10.1245/s10434-025-18664-0↗
- Paper ASO Visual Abstract: Factors Driving Attrition from Neoadjuvant Therapy to Pancreatectomy in Localized Pancreatic Cance… DOI 10.1245/s10434-025-18846-w↗
- Paper ASO Author Reflections: Racial Disparities in Chemoresponsivity in Localized Pancreatic Cancer: Nature or Nurture? DOI 10.1245/s10434-022-12843-z↗
- Peter J. Hosein · 4 shared papers, 2024–2026 · strength 1.00
- Paper Factors Driving Attrition from Neoadjuvant Therapy to Pancreatectomy in Localized Pancreatic Cancer. DOI 10.1245/s10434-025-18664-0↗
- Paper ASO Visual Abstract: Factors Driving Attrition from Neoadjuvant Therapy to Pancreatectomy in Localized Pancreatic Cance… DOI 10.1245/s10434-025-18846-w↗
- Paper Improving patient stratification and selection for curative-intent treatment in localized pancreatic cancer. DOI 10.21037/hbsn-23-668↗
- Matthew H. G. Katz · 3 shared papers, 2021–2022 · strength 0.75
- Paper A patient-centered, multidisciplinary approach to treating borderline resectable pancreatic adenocarcinoma. DOI 10.21037/cco-22-86↗
- Paper Thumbprinting Locally Advanced Pancreatic Cancer: Have We Developed the Optimal Staging System? DOI 10.1245/s10434-021-10181-0↗
- Paper Radiographic and Serologic Response to First-Line Chemotherapy in Unresected Localized Pancreatic Cancer. DOI 10.6004/jnccn.2022.7018↗
- Shishir Kumar Maithel · 3 shared papers, 2024–2025 · strength 0.63
- Paper Neighborhood Disadvantage is Associated with Worse Pathologic Response in Pancreatic Cancer. DOI 10.1245/s10434-025-17024-2↗
- Paper Intersection of Black race and carbohydrate antigen 19-9 nonproduction underpins worse pathologic response to neoadjuva… DOI 10.1002/cncr.70130↗
- Paper Lymph node metrics following neoadjuvant therapy to refine patient selection for adjuvant chemotherapy in resected panc… DOI 10.1002/jso.27798↗
- Jashodeep Datta · 3 shared papers, 2024–2025 · strength 0.60
- Paper Improving patient stratification and selection for curative-intent treatment in localized pancreatic cancer. DOI 10.21037/hbsn-23-668↗
- Paper Intersection of Black race and carbohydrate antigen 19-9 nonproduction underpins worse pathologic response to neoadjuva… DOI 10.1002/cncr.70130↗
- Paper Lymph node metrics following neoadjuvant therapy to refine patient selection for adjuvant chemotherapy in resected panc… DOI 10.1002/jso.27798↗
- Gretel Terrero · 2 shared papers, 2026 · strength 0.56
- Ifeanyichukwu Chinedu Ogobuiro · 2 shared papers, 2023–2024 · strength 0.43
- Paper ASO Author Reflections: Racial Disparities in Chemoresponsivity in Localized Pancreatic Cancer: Nature or Nurture? DOI 10.1245/s10434-022-12843-z↗
- Paper Lymph node metrics following neoadjuvant therapy to refine patient selection for adjuvant chemotherapy in resected panc… DOI 10.1002/jso.27798↗
- Haleh Amirian · 2 shared papers, 2024 · strength 0.39
- David A. Kooby · 2 shared papers, 2024–2025 · strength 0.37
- Paper Intersection of Black race and carbohydrate antigen 19-9 nonproduction underpins worse pathologic response to neoadjuva… DOI 10.1002/cncr.70130↗
- Paper Lymph node metrics following neoadjuvant therapy to refine patient selection for adjuvant chemotherapy in resected panc… DOI 10.1002/jso.27798↗
- Alexander A. Parikh · 2 shared papers, 2024–2025 · strength 0.37
- Paper Intersection of Black race and carbohydrate antigen 19-9 nonproduction underpins worse pathologic response to neoadjuva… DOI 10.1002/cncr.70130↗
- Paper Lymph node metrics following neoadjuvant therapy to refine patient selection for adjuvant chemotherapy in resected panc… DOI 10.1002/jso.27798↗
- Daniel Erik Abbott · 2 shared papers, 2024–2025 · strength 0.37
- Paper Intersection of Black race and carbohydrate antigen 19-9 nonproduction underpins worse pathologic response to neoadjuva… DOI 10.1002/cncr.70130↗
- Paper Lymph node metrics following neoadjuvant therapy to refine patient selection for adjuvant chemotherapy in resected panc… DOI 10.1002/jso.27798↗
- Syed Nabeel Zafar · 2 shared papers, 2024–2025 · strength 0.37
- Paper Intersection of Black race and carbohydrate antigen 19-9 nonproduction underpins worse pathologic response to neoadjuva… DOI 10.1002/cncr.70130↗
- Paper Lymph node metrics following neoadjuvant therapy to refine patient selection for adjuvant chemotherapy in resected panc… DOI 10.1002/jso.27798↗
- Patricio Marcelo Polanco · 2 shared papers, 2020–2023 · strength 0.28
- Adam Charles Yopp · 2 shared papers, 2020–2023 · strength 0.28
- Matthew R. Porembka · 2 shared papers, 2020–2023 · strength 0.28
- Sam C. Wang · 2 shared papers, 2020–2023 · strength 0.28
- Herbert J. Zeh · 2 shared papers, 2020–2023 · strength 0.28
- Syed Ameen Ahmad · 1 shared paper, 2025 · strength 0.21
- Kawther Abdilleh · 1 shared paper, 2025 · strength 0.21
- Julia Button · 1 shared paper, 2025 · strength 0.19
- David G. Brauer · 1 shared paper, 2025 · strength 0.19
- Michael E. Lidsky · 1 shared paper, 2025 · strength 0.19
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.